| 发明名称 |
CDCP1 AND BREAST CANCER |
| 摘要 |
The present invention relates to a method for treating breast cancer in a subject having a hyperactivation of the Epidermal Growth Factor Receptor 1 and/or 2 (EGFR and/or ErbB2 HER2), as compared to the normal subject population, or expressing deltaHER2, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the CUB domain-containing protein 1 (CDCP1). |
| 申请公布号 |
US2014363448(A1) |
申请公布日期 |
2014.12.11 |
| 申请号 |
US201214366707 |
申请日期 |
2012.12.21 |
| 申请人 |
NOVARTIS AG ;NOVARTIS FORSCHUNGSSTIFTUNG |
发明人 |
Bentires-Alj Mohamed;Voshol Johannes;Alajati Abdullah;Bonenfant Deborah |
| 分类号 |
C07K16/30;C12N15/113 |
主分类号 |
C07K16/30 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating cancer in a subject having a hyperactivation of the Epidermal Growth Factor Receptor 1 and/or 2 (EGFR and/or ErbB2/HER2), as compared to the normal subject population, or expressing deltaHER2, said method comprising the step of administering to said subject a therapeutically effective amount of a modulator of the CUB domain-containing protein 1 (CDCP1). |
| 地址 |
Basel CH |
